Tebentafusp (Kimmtrak)

Mechanism of action

Bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells.

Diseases for which it is used

• Uveal melanoma

History of changes in FDA indication

• 1/25/2022: Approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. (Based on IMCgp100-202)

History of changes in EMA indication

• 4/1/2022: Initial authorization as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Also known as

• Code name: IMCgp100
• Generic name: tebentafusp-tebn
• Brand name: Kimmtrak